Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology

Shunsuke Koga, Maiko Ono, Naruhiko Sahara, Makoto Higuchi, Dennis W Dickson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The tau PET ligand 2-((1E,3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([11C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [11C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. Method: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden. PBB3 fluorescence labeling, double or single immunostaining for α-synuclein and phospho-tau, Prussian blue staining, and in vitro autoradiography with [11C]PBB3 were performed for these selected samples. Results: PBB3 fluorescence labeled various α-synuclein lesions including Lewy bodies, Lewy neurites, spheroids, glial cytoplasmic inclusions, and neuronal cytoplasmic inclusions. Meanwhile, autoradiographic labeling with [11C]PBB3 at 10 nM demonstrated no significant binding in Lewy body disease cases. In contrast, significant autoradiographic binding of [11C]PBB3 to the striatopallidal fibers was found in 2 MSA cases, which had high densities of glial cytoplasmic inclusions without tau or iron deposits in this region. Conclusions: Given that the maximum concentration of [11C]PBB3 in human PET scans is approximately 10 nM, the present data imply that α-synuclein pathology in Lewy body disease is undetectable by [11C]PBB3-PET, whereas those in a subset of MSA cases with high densities of glial cytoplasmic inclusions could be captured by this radioligand.

Original languageEnglish (US)
Pages (from-to)884-892
Number of pages9
JournalMovement Disorders
Volume32
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Synucleins
Multiple System Atrophy
Fluorescence
Lewy Body Disease
Pathology
Ligands
Inclusion Bodies
Neuroglia
Lewy Bodies
Brain
Neurites
2-(4-(6-(methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo(d)thiazol-6-ol
Autoradiography
Positron-Emission Tomography
Iron
Staining and Labeling

Keywords

  • autoradiography
  • Lewy body disease
  • multiple system atrophy
  • PBB3
  • α-synucleinopathy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology. / Koga, Shunsuke; Ono, Maiko; Sahara, Naruhiko; Higuchi, Makoto; Dickson, Dennis W.

In: Movement Disorders, Vol. 32, No. 6, 01.06.2017, p. 884-892.

Research output: Contribution to journalArticle

Koga, Shunsuke ; Ono, Maiko ; Sahara, Naruhiko ; Higuchi, Makoto ; Dickson, Dennis W. / Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology. In: Movement Disorders. 2017 ; Vol. 32, No. 6. pp. 884-892.
@article{a96e249335764574ac04505eed60ab21,
title = "Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology",
abstract = "Background: The tau PET ligand 2-((1E,3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([11C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [11C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. Method: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden. PBB3 fluorescence labeling, double or single immunostaining for α-synuclein and phospho-tau, Prussian blue staining, and in vitro autoradiography with [11C]PBB3 were performed for these selected samples. Results: PBB3 fluorescence labeled various α-synuclein lesions including Lewy bodies, Lewy neurites, spheroids, glial cytoplasmic inclusions, and neuronal cytoplasmic inclusions. Meanwhile, autoradiographic labeling with [11C]PBB3 at 10 nM demonstrated no significant binding in Lewy body disease cases. In contrast, significant autoradiographic binding of [11C]PBB3 to the striatopallidal fibers was found in 2 MSA cases, which had high densities of glial cytoplasmic inclusions without tau or iron deposits in this region. Conclusions: Given that the maximum concentration of [11C]PBB3 in human PET scans is approximately 10 nM, the present data imply that α-synuclein pathology in Lewy body disease is undetectable by [11C]PBB3-PET, whereas those in a subset of MSA cases with high densities of glial cytoplasmic inclusions could be captured by this radioligand.",
keywords = "autoradiography, Lewy body disease, multiple system atrophy, PBB3, α-synucleinopathy",
author = "Shunsuke Koga and Maiko Ono and Naruhiko Sahara and Makoto Higuchi and Dickson, {Dennis W}",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/mds.27013",
language = "English (US)",
volume = "32",
pages = "884--892",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology

AU - Koga, Shunsuke

AU - Ono, Maiko

AU - Sahara, Naruhiko

AU - Higuchi, Makoto

AU - Dickson, Dennis W

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: The tau PET ligand 2-((1E,3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([11C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [11C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. Method: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden. PBB3 fluorescence labeling, double or single immunostaining for α-synuclein and phospho-tau, Prussian blue staining, and in vitro autoradiography with [11C]PBB3 were performed for these selected samples. Results: PBB3 fluorescence labeled various α-synuclein lesions including Lewy bodies, Lewy neurites, spheroids, glial cytoplasmic inclusions, and neuronal cytoplasmic inclusions. Meanwhile, autoradiographic labeling with [11C]PBB3 at 10 nM demonstrated no significant binding in Lewy body disease cases. In contrast, significant autoradiographic binding of [11C]PBB3 to the striatopallidal fibers was found in 2 MSA cases, which had high densities of glial cytoplasmic inclusions without tau or iron deposits in this region. Conclusions: Given that the maximum concentration of [11C]PBB3 in human PET scans is approximately 10 nM, the present data imply that α-synuclein pathology in Lewy body disease is undetectable by [11C]PBB3-PET, whereas those in a subset of MSA cases with high densities of glial cytoplasmic inclusions could be captured by this radioligand.

AB - Background: The tau PET ligand 2-((1E,3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([11C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [11C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. Method: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden. PBB3 fluorescence labeling, double or single immunostaining for α-synuclein and phospho-tau, Prussian blue staining, and in vitro autoradiography with [11C]PBB3 were performed for these selected samples. Results: PBB3 fluorescence labeled various α-synuclein lesions including Lewy bodies, Lewy neurites, spheroids, glial cytoplasmic inclusions, and neuronal cytoplasmic inclusions. Meanwhile, autoradiographic labeling with [11C]PBB3 at 10 nM demonstrated no significant binding in Lewy body disease cases. In contrast, significant autoradiographic binding of [11C]PBB3 to the striatopallidal fibers was found in 2 MSA cases, which had high densities of glial cytoplasmic inclusions without tau or iron deposits in this region. Conclusions: Given that the maximum concentration of [11C]PBB3 in human PET scans is approximately 10 nM, the present data imply that α-synuclein pathology in Lewy body disease is undetectable by [11C]PBB3-PET, whereas those in a subset of MSA cases with high densities of glial cytoplasmic inclusions could be captured by this radioligand.

KW - autoradiography

KW - Lewy body disease

KW - multiple system atrophy

KW - PBB3

KW - α-synucleinopathy

UR - http://www.scopus.com/inward/record.url?scp=85018663104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018663104&partnerID=8YFLogxK

U2 - 10.1002/mds.27013

DO - 10.1002/mds.27013

M3 - Article

VL - 32

SP - 884

EP - 892

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -